Home Blog

Tafasitamab/Lenalidomide Shows Efficacy, Tolerability for R/R DLBCL


During a live virtual event, Brian T. Hill, MD, discussed the results of the L-MIND study of tafasitamab plus lenalidomide for patients with relapsed/refractory diffused B-cell lymphoma.

Targeted OncologyTM: Please describe the study design and patient population of the L-MIND study (NCT02399085) of tafasitamab (Monjuvi) and lenalidomide (Revlimid).

HILL: The L-MIND study was a single-arm, open-label, multicenter, phase 2 study of tafasitamab plus lenalidomide for patients with relapsed/refractory diffused large B-cell lymphoma [DLBCL], having anywhere from 1 to 3 prior lines of therapy. Patients could not be eligible for high-dose chemotherapy and autologous stem cell transplant. Patients with primary refractory DLBCL were excluded, which is something that we should take into account when interpreting the results.

The treatment was tafasitamab which is an intravenously administered monoclonal antibody targeting CD19. It was given at a standard dose on days 1, 8, 15, 22 for 3 [28-day] cycles, meaning weekly for 12 weeks. The cycles overlapped with a full 25 mg dose of lenalidomide on days 1 to 21, with 7 days off on 28-day cycles. For patients who were responding after 3 cycles, the tafasitamab was reduced to every other week starting in cycle 4 and continued up to 12 cycles. For patients who had stable disease or better after 12 cycles, they could continue tafasitamab without lenalidomide until disease progression. The primary end point was an overall response rate [ORR]with secondary end points including progression-free survival [PFS].

There were 81 patients with a median age of 72 years old, with a pretty wide range [from 41 to 86]. International Prognostic Index scores were [evenly divided between 0-2 and 3-5].1 Most of the patients had advanced stage disease and elevated LDH [lactate dehydrogenase]. They had a median of 2 lines of prior therapy. There were some primary refractory patients, [making up] 19%; I believe the study was amended somewhere along the line to exclude those, but about 44% were refractory to the prior line of therapy. Most of these patients have not had a prior stem cell transplant, and cell of origin was skewed towards non-germinal center or indeterminate cell type.

What were the results of this study in terms of efficacy?

The complete authorization [CR] rate was 40%, with 17% partial responses [PR], 16% stable disease, and 26% who had either progressive disease or were not evaluable. The ORR was 57%, and the median duration of response was 44 months.

[In terms of] PFS for all comers, [median PFS was 11.6 months, and] There are patients who had a CR who had very good [long-term] outcomes, and I think it is pretty remarkable that the lenalidomide was only given for 12 months, and beyond that they just were getting infusions with tafasitamab every 2 weeks. There was almost a plateau in the PFS curves going out 3 to 4 years. And so, the media overall survival [OS] after 3 and a half years of follow-up, was [33.5] months.

Looking at the efficacy based on a number of prior lines of therapy, not surprisingly, patients with 1 prior line of therapy tended to do better. The CR rate was almost 50% [in patients with] 1 prior line of therapy, whereas it dropped down to 32% in patients with 2 or more prior lines of therapy. The ORR was 67% for patients with 1 prior line of therapy, whereas it was down to 47% [in those with] 2 or more prior lines of therapy. And similarly, OS was much better in the patients with 1 prior line of therapy.

What was the toxicity profile observed in the L-MIND trial?

I’m sure many physicians are using lenalidomide for their patients with multiple myeloma, or those with myelodysplastic syndrome, so they are familiar with the adverse event [AE] profile of lenalidomide. There was a cumulative rate of neutropenia: 27% had grade 3, and 21% had grade 4. There was a total of 12% who experienced grade 3 or grade 4 febrile neutropenia.

[In terms of] common non-hematologic AEs, they mirror what probably should look familiar for lenalidomide, which is that diarrhea can occur in about a third of patients. You have these other unusual AEs like cough, edema, arthralgias, and back pain. Interestingly, 16% experienced constipation. I’m never sure which way to tell whether patients are going to get diarrhea or are they going to get constipation; it’s hard to predict. There are other AEs like muscle spasms, nausea, abdominal pain, and so forth. They are not much different than the AEs that we see with lenalidomide in general.

The neutropenia is much more common in the 12 months of the combination with lenalidomide, with almost 50% having some neutropenia. Anemia, thrombocytopenia, diarrhea, asthenia are follows. For patients who go a full year, and then get on to the maintenance phase of tafasitamab every other week, AEs were pretty minimal.

The rate of serious AEs was 51%, but the rate of serious AEs suspected to be treatment-related was 19%. So, a lot of the AEs may have been disease-related. [The rate of] discontinuations due to AEs was 12%.

AEs of special interest included AEs like secondary cancers, tumor flare reaction, deep vein thrombosis [DVT], and so forth. What I thought was interesting is that there were, that I can tell, no pulmonary embolism [PE] or DVT deaths, because thrombosis is a known toxicity or risk factor with lenalidomide, and patients did need to have DVT and PE prophylaxis on this study.2

The rate of AEs leading to death was 13%.1 There were 4 deaths out of 30 [in the safety cohort] that were treatment-emergent AEs leading to death. None were considered to be related to study treatment. If there is a death on a clinical trial from some complication, but the investigator deems it not related to the study treatment, then it gets counted as a study-related death, but then the attribution is not always clear. This is a high-risk patient population for AEs.

What did the RE-MIND study (NCT04150328) show about the tafasitamab/lenalidomide combination?

One of the concerns about single-arm trials is, “What are we comparing it with?” [Data from the RE-MIND study] was presented at the 2021 American Society for Clinical Oncology annual meeting.3 It was an attempt to compare the benefit of tafasitamab when combined with lenalidomide, compared with lenalidomide by itself.

This is a retrospective analysis where [the investigators] collected data on several hundred patients with DLBCL who were treated with lenalidomide as a monotherapy; and then, attempted to adjust for all these baseline co-variants with a matched profitability scoring method, and wound up with patients they felt were reasonably matched, and showed that there was a much higher ORR, CR rate, and PR rate with tafasitamab compared to with lenalidomide monotherapy. I’m not sure how much weight to put into these results [since] it wasn’t a randomized trial, but I think it does suggest that the tafasitamab is doing something, it’s not just the lenalidomide that’s doing the heavy lifting here.


1. Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffused large B-cell lymphoma. Haematologica. 2021;106(9):2417-2426. doi:10.3324/haematol.2020.275958

2. Lenalidomide (Revlimid). Prescribing information. Celgene Corporation; 2013. Accessed May 23, 2022. https://bit.ly/3wEwczG

3. Zinzani PL, Rodgers T, Marino D, et al. RE-MIND: Comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffused large B-cell lymphoma. Clin Cancer Res. 2021;27(22):6124-6134. doi:10.1158/1078-0432.CCR-21-1471


Metro Transportation Licensing Commission sets rules for party vehicles


  • Metro Transportation Licensing Commission sets rules for party vehicles

In a crowded jury assembly room, Mayor John Cooper stood before the Metro Transportation Licensing Commission and spoke strong words.

“It’s time to regulate the party,” he said.

Cooper, along with At-Large Council Member Bob Mendes, appeared before the commission’s monthly meeting Thursday to be put on record about the draft rules for Nashville’s entertainment vehicles.

The Mayor asked for an 11 pm curfew and restrictions during rush hour. He said he saw no reason to have unenclosed vehicles on Nashville’s streets. Those were just two of the issues the commission took up during the nearly six-hour meeting.

Party vehicle regulations:Owners, local groups spar over routes, noise and operating hours

Previously:With the state’s party vehicle bill on Gov. Lee’s desk, Nashville refines local regulations

How Couples Should Decide Whether Counselling Is Worth It, According to Therapists


Marriage counseling can be difficult, but it is often wise to invest time in your relationship to see if it can be improved. About 44% of couples go to marriage counseling prior to tying the knot. Research also suggests that couples therapy positively impacts 70% of couples receiving treatment. A couples counsellor is unbiased by design, so if you want to work through problems with your significant other, they can provide an outside perspective. It is also a plus that the outside perspective comes from someone who is highly trained in relationship issues. But how do you know when it’s right for you?

Signs you and your partner may need couples counseling

Dr. Gavin Shafron, a New York state-licensed psychologist and couples counsellor at Clarity Therapy NYC, says there are many different reasons a couple could start counseling, one of which is constant conflict. “I often see couples come to therapy when they find themselves in the same repetitive arguments again and again, or when they are concerned about the sustainability or healthiness of their current dynamic.”

Dr. Saliha Bava, a licensed marriage and family therapist and author of The Relational Book for Parenting expanded on this: “I’ve had couples who come in and find they are…getting into conflict and they feel tension, not necessarily fighting, but even still there’s tension in the body. Something feels off and you might say she’s not listening, she’s not getting me.” This distinction is important because, while it might be obvious if there’s a lot of outward fighting, this general tension is often overlooked.

According to Bava, counseling is all about honoring each other’s differences and finding a middle ground. Sometimes a couple may not have “the language or the way to talk with each other because they are too caught up in their differences.”

Communication skills are the cornerstone to healthy relationships. Remember that the decision to enter therapy is entirely your own, but if you are struggling with issues around communication, counseling is a good place to start.

What to do if you’re still unsure

If you or your partner are still unsure if couples counseling is right for you, it’s time to do some reflection. Shafron recommends considering, “What challenges [you or your partner] about the idea of ​​entering counseling?”

He went on, “For some, there may be fear that something will come out in the course of therapy that derails their relationship further, or at worst, ends the relationship, so the lack of readiness can be very existential. For others, there can be shame around their actions or the issues that exist in their relationship. Sometimes, it can be a combination of a number of factors.”

These assumptions can definitely get in the way of pursuing therapy, but remember that a couples counsellor is trained to be neutral. Two helpful questions to ask yourself before starting therapy are whether you feel the challenges in your relationship are already being addressed or if you feel a change needs to happen. Ultimately, the goal of therapy is always building new communication skills and healing wounds together.

Bava also recommends researching as much as possible beforehand. This doesn’t just mean a quick Google search, but actually might mean calling a few therapists to see if they feel right for you. “Most therapists that I know will do a five- to 10-minute call, and you can ask questions and see if it’s a good fit to start out with.” She also recommends trying at least three sessions before you decide for sure it isn’t for you.

When isn’t couples therapy worth it?

Counseling isn’t necessarily for everyone. As Bava explained, “It comes back to what you are looking for in counseling. If you’re seeing it as a quick fix, like a pill, it might not work. It’s a process. You have to be willing to engage in a process.”

Shafron added, “Some come to counseling with the goal of changing traits or characteristics of who their partner is. This isn’t the best use of couples counseling because therapy isn’t about changing the character or personality of another person in order to make a relationship work.” If you aren’t willing to put in the effort and do the (at times) difficult work that comes along with couples counseling, then maybe it’s time to consider other options.

Ultimately, starting couples therapy is a decision that needs to be made by both partners. It is one that requires some reflection, but if you are ready to put in the effort, it can be incredibly healing for your relationship.

Carolyn Hax: Can I stop visiting my children’s grandmother?


Placeholder while article actions load

We asked readers to channel their inner Carolyn Hax and answer this question. Some of the best responses are below.

Dear Carolyn: For years, I’ve done all the heavy lifting of maintaining a relationship between my children and their paternal grandmother — even after my divorce five years ago. Recently, my ex did finally try to arrange a visit and she rebuffed him and his new family. Her loss — her new DIL is frankly nicer than me and her kids are polite and adorable.

I normally let her know when I am coming to town and see if she can/wants to get together — my ex and I both live very far away but I regularly travel to see my parents who live a manageable distance away, and my ex does not normally travel that way. I have always done all the driving (two hours each way, a complete tour of the suburbs) — her health genuinely doesn’t permit it now, but even when she COULD drive, she visited us twice in 15 years of marriage and never met my parents. Can I just … not do that anymore? How do I balance “I might regret neglecting a lonely ill person” with “But she makes it so hard and I’m tired and she’s not even my relative”?

Anonymous: You don’t have a responsibility to a former in-law, but you do have a responsibility to your children, so try framing it in that direction: Is their grandmother a positive or negative presence in their lives? Does visiting her enhance their relationship with her? Do they want to spend time with her? Can they do so on their own (are they old enough/responsible enough to make the two-hour drive when you’re visiting your own parents)?

Regarding the potential regret that you might feel, our lives are filled with choices, decisions, things we can do, could have done — because we cannot do all things or be all things. Weigh how great that regret might be against the burden of effort and feelings of resentment. Give yourself permission to value your own time, your own emotions, and see where the balance lands.

Anonymous: You have permission. But you can also compromise here. Consider visiting every other time you come to town or only if your schedule allows. If you are still feeling guilty, consider if there are other, less travel-intensive ways that you can keep grandma connected to grandkids like photo sharing frames and video calls. The best part is, your kids may be even more adept than you at making the technology work, giving you a break from bearing all of the responsibility of staying connected.

Anonymous: Given she is unable to travel, before you end the visits, ask the ex-husband to take on the responsibility of the visits. Explain you made the effort over the years for the benefit of both ex-MIL and children post-divorce, but feel that since enough time and healing has occurred for the children, and his mother is less mobile, it’s time for him to take over coordinating the visits between his mother and the children.

It’s not unreasonable to ask the ex-husband to manage the relationship between his mother and children.

Explain you did not want to abruptly end these visits out of concern for ex-MIL mental well-being. So you are allowing him to step in to make a seamless transition. Then you both should tell his mother he will handle the visits going forward.

Anonymous: I’d advise that it depends on what your children get out of the visits. It’s really about them and their relationship with their grandmother, and not about her or you or your ex. You don’t mention how they feel about these visits at all, which I find strange. If they love her and want a relationship with her to continue, then you should keep making the effort to visit. If the relationship doesn’t benefit them, then I’d say you can stop. But I’d talk to them about it first if you’re not sure. Not to ask them the same way you’ve asked Carolyn, but a much more general conversation about how they feel about their grandmother and visiting her. Don’t put the decision on them, just be clear about what they get from these visits.

Every week, we ask readers to answer a question submitted to Carolyn Hax’s live chat or email. Read the most recent installment here. New questions are typically posted on Fridays, with a Monday deadline for submissions. Responses are anonymous unless you choose to identify yourself and are edited for length and clarity.

Quick-relief Asthma Drugs Market 2022 by Key Players, Regions, Type and Application, Forecast to 2030 – ManufactureLink


Quick-relief Asthma Drugs Market Research report is a professional and in-depth market report that focuses on primary and secondary drivers, market share, possible sales volume, leading segments and geographical analysis of a industry. It shows that the rise in market value is generally attributed to the rising growth of the application industries and the subsequent rise in demand of applications. This market analysis report gives an examination of various segments that are relied upon to witness the quickest growth amid the approximate forecast frame. The competitive landscape section of the A global business report brings into light a clear insight about the market share analysis of major industry players.

Market segmentation

Quick-relief Asthma Drugs market is split by Type and by Application. For the period 2018-2030, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

⦿ Tablet

⦿ Spray

Market segment by Application, can be divided into

⦿ Hospital Pharmacy

⦿ Online Pharmacy

⦿ Retail Pharmacy

Market segment by players, this report covers

⦿ Pfizer

⦿ GlaxoSmithKline

⦿ Novartis

⦿ Merck

⦿ Boehringer Ingelheim

⦿ AstraZeneca

⦿ Roche

⦿ Teva Pharmaceutical

⦿ Vectura Group

Market segment by regions, regional analysis covers

⦿ North America (United States, Canada, and Mexico)

⦿ Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

⦿ Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

⦿ South America (Brazil, Argentina, Rest of South America)

⦿ Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Quick-relief Asthma Drugs product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Quick-relief Asthma Drugs, with revenue, gross margin and global market share of Quick-relief Asthma Drugs from 2019 to 2021.

Chapter 3, the Quick-relief Asthma Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Quick-relief Asthma Drugs market forecast, by regions, type and application, with revenue, from 2021 to 2026.

Chapter 11 and 12, to describe Quick-relief Asthma Drugs research findings and conclusion, appendix and data source.

Click The Link To Get A Free Sample Copy Of The Report @ https://crediblemarkets.com/sample-request/quick-relief-asthma-drugs-market-424505?utm_source=Amruta&utm_medium=SatPR

Some Point from Table of Content:

Global Quick-relief Asthma Drugs Market Overview: It includes six chapters, research scope, major manufacturers covered, market segments by type, Quick-relief Asthma Drugs market segments by application, study objectives, and years considered.

Global Quick-relief Asthma Drugs Market Landscape: Here, the competition in the Worldwide Quick-relief Asthma Drugs Market is analysed, by price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Global Quick-relief Asthma Drugs Market Profiles of Manufacturers: Here, leading players of the global Quick-relief Asthma Drugs market are studied based on sales area, key products, gross margin, revenue, price, and production.

Global Quick-relief Asthma Drugs Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Quick-relief Asthma Drugs Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Global Quick-relief Asthma Drugs Market Application or End User: This section of the research study shows how different end-user/application segments contribute to the global Quick-relief Asthma Drugs Market.

Global Quick-relief Asthma Drugs Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Global Quick-relief Asthma Drugs Market: Customization Available

While syndicate research services are among our most sought-after offerings, we like our clients to be aware of the clear fact that the insights in syndicated reports may not be specific enough at times to cater to research demands of a particular organization. Here’s when custom research services step in. Tailor-made research reports support specific research needs of a business, including an extensive survey or an exclusive research methodology. Irrespective of how niche a market is, custom research services that we offer at Credible Markets complement the most critical industry research needs.

We understand that organizations are keen on gaining access to trending market insights, but we also know that a one-size-fits-all approach doesn’t work all the time. Our custom research services help our clients across diverse industry sectors make sound business decisions based on our laser-focused research, targeted at their specific industry and line of business.

Direct Purchase Quick-relief Asthma Drugs Market Research Report Now @ https://crediblemarkets.com/reports/purchase/quick-relief-asthma-drugs-market-424505?license_type=single_user;utm_source=Amruta&utm_medium=SatPR

Important Questions Answered

  • What is the growth potential of the Quick-relief Asthma Drugs market?
  • Which company is currently leading the Quick-relief Asthma Drugs market? Will the company continue to lead during the forecast period 2022-2030?
  • What are the top strategies that players are expected to adopt in the coming years?
  • Which regional market is anticipated to secure the highest market share?
  • How will the competitive landscape change in the future?
  • What do players need to do to adapt to future competitive changes?
  • What will be the total production and consumption in the Quick-relief Asthma Drugs Market by 2030?
  • Which are the key upcoming technologies? How will they impact the Quick-relief Asthma Drugs Market?
  • Which product segment is expected to show the highest CAGR?
  • Which application is forecast to gain the biggest market share?

Why Choose Credible Markets?

To help organizations in pharmaceuticals industry, our reports provide in-depth insights on R&D approached of market leaders, drug development and clinical trial capacities, research pipelines, FDA approvals, pricing strategies, raw material sourcing, and demand-supply-distribution networks. Branded and non-branded generics, specialty drugs, and several other sub-sectors are thoroughly analyzed in pharma industry reports.

On another side, medical devices industry stands with a totally different set of challenges and growth opportunities. Delivering valued insights on creation and maintenance of product competency, the medical devices industry market reports allow for better understanding of the medical devices ecosystem and development of competent business models aiming at long-term growth.

About Credible Markets:

Credible Markets is a new-age market research company with a firm grip on the pulse of global markets. Credible Markets has emerged as a dependable source for the market research needs of businesses within a quick time span. We have cooperated with leading publishers of market intelligence and the coverage of our reports reserve spans all the key industry verticals and thousands of micro markets. The massive repository allows our clients to pick from recently published reports from a range of publishers that also provide extensive regional and country-wise analysis. Moreover, pre-booked research reports are among our top offerings.

Contact Us:

Credible Markets Analytics Pvt Ltd
US: +1(929)-450-2887
99 Wall Street 2124 New York, NY 10005
Email: [email protected]
Follow US: Linkedin | Facebook | Twitter

Fume all you want, don’t hit erratic drivers in front of you


No matter how much a driver might fume about the slow driver ahead, the driver behind him is still responsible for maintaining a safe distance to avoid a collision — even if the slow driver tries to block the driver behind him from passing, or stops suddenly in the middle of the street because he might have seen a cat under a parked car.

Insurers typically assign fault to drivers who follow too closely behind others, creating the risk of a fender-bender in case of a sudden stop. And BC’s Civil Resolution Tribunal found the province’s public insurer was not wrong in assigning partial fault to the following driver in Dusdal v. ICBC.

ICBC insured both vehicles involved in a collision on Oct. 8, 2021 in Campbell River, BC

ICBC found Jacob Dusdal and the driver in front of him, identified as “RS,” were equally responsible for the collision. Dusdal disagreed, and went to the CRT for reimbursement of the $1,250 deductible he had to pay to fix his car. Under the province’s Insurance (Vehicle) Actif Dusdal is not responsible for the accident, ICBC must pay for his vehicle repairs, including the deductible.

The court referred to evidence that “the parties were involved in somewhat of a conflict while driving prior to the accident.”

Dusdal testified that RS was driving erratically ahead of him. He said he gave RS a “fairly polite honk” on Lal Road for driving slowly. According to Dusdal’s evidence, he tried to “very slowly” pass RS on the left when RS “suddenly” drove forward to “block” him.

RS says he was driving on South Murphy Street with Dusdal following closely behind him. To allow Dusdal to pass, RS said he turned left onto Lal Road, thinking Dusdal would continue on South Murphy Street. However, Mr. Dusdal also turned left onto Lal Road.

RS described Dusdal’s perception of a “block” maneuver as a realization that, as RS turned right onto Galerno Road (where the collision occurred), Dusdal tried to overtake his vehicle on the left at the same time RS was turning. RS said he realized there was not enough room for the two vehicles to do the left together, so as he completed his turn, Dusdal pulled in back behind him.

As both cars drove straight along Galerno Road, RS noticed a parked car to his right. He thought he saw a cat coming out from under the parked car, so he “applied his brakes firmly but not spiked.” Dusdal hit his vehicle from behind.

ICBC assigned fault to both drivers. And the CRT agreed.

“I find it likely that RS was driving negligently in positioning his vehicle and stopping in the middle of the road,” CRT vice chair Andrea Ritchie wrote in her decision. “Although there is no cat seen in the video footage, I find that does not mean one was not present. I also note from the video footage the stop is not overly sudden. However, given the circumstances, I find RS stopping in the manner he did was in breach of section 144 of the MVA (Motor Vehicle Act).

“But I also find Mr. Dusdal was negligent in the circumstances. I say this because Mr. Dusdal’s own account of RS’s driving behavior leading up to the accident should have led Mr. Dusdal to keep a greater distance between their vehicles. Whether RS ​​saw a cat, other hazard, or stopped for no reason, I find Mr. Dusdal was following too closely behind RS given the events that had already occurred.”

Feature image courtesy of iStock.com/Believe_In_Me

On Women’S Health Day 2022, Here’S Some Expert Advice For New Mothers Trying To Beat Postpartum Depression


From being happy and excited to feel sad, anxious and fearful, a new mother might experience and emotional rollercoaster soon after giving birth. If this mental turmoil persists for more than two weeks, one should be alarmed, for it could be a condition called ‘postpartum depression.’

Postpartum depression, or PPD in short, is much more than just mild ‘mood swings.’ As the name itself suggests, postpartum depression is depression that is to witness among new mothers after childbirth. PPD “often starts within one to three weeks after a childbirth” but unlike ‘baby blues,’ it may last for ‘weeks or months at a time’, the National Institute of Health and Family Welfare said.

‘Baby blues’ is a term to describe the crying spells, irritability, sadness, sleeping issues and tiredness that a woman might experience after having a child. Its symptoms are likely to subside within a week or two. But if the feeling of depression lasts longer than two weeks and is more serious in nature, then one might be suffering from postpartum depression.

Symptoms of postpartum depression include severe mood swings, difficulty bonding with the baby, loss of appetite or eating too much, insomnia, fatigue, fear of not being a good mother, feelings of worthlessness, shame or guilt and getting frequent panic attacks. Suffering from depression, some women might even become suicidal or think of harming their baby themselves, the Mayo Clinic said in one of its reports.

“Symptoms usually develop within the first few weeks after giving birth, but may begin earlier ― during pregnancy ― or later — up to a year after birth,” it said.

Two years ago, the COVID-19 pandemic came in and not just robbed millions of their livelihood, but it also severely impacted mental health. According to the World Health Organization (WHO), the “global prevalence of anxiety and depression increased by a massive 25 percent” in the first year of the COVID-19 pandemic.

In its report published in March this year, the WHO also cited the finding of the Global Burden of Disease study. The global health body said the study suggested that “women have been more severely impacted than men…”

Moreover, a study published in the National Library of Medicine published this year revealed that “the prevalence of PPD in women is relatively high during COVID-19.” Back in 2017, a study focusing on India showed a “high prevalence of postpartum depression in Indian mothers.”

During pregnancy, a woman experiences many hormonal changes. Sometimes, her relationship with her partner, financial and family issues, and even lifestyle factors might add to their women, degrading mental health.

The surge in the number of women suffering from PPD during COVID-19 may be a result of fear associated with the pandemic. “What happened is that all kinds of mental issues became more prominent. People have techniques to cope with stress. They go to movies, go to the gym…but that coping was denied due to restrictions imposed during COVID-19. This led to an increase in all kinds of mental health problems, even postpartum depression,” Dr. Vishal Chabbra, Senior Consultant Psychiatrist, Fortis, said.

“Mothers had fear…some people died when they had COVID pregnancy and they were pregnant. That stress was there for a lot of people when the COVID came… people delayed pregnancy sometimes, they were sceptical about,” Dr Chabbra said .

A counseling psychologist based in Bengaluru, Dr Diana Sam, said: “All therapists in this field would accept that there was a surge in mental health issues, that led to many people reaching out for help… COVID-19 is still causing stress. among individuals. Pregnancy, on the other hand, also causes stress.”

Dr Sam, who has helped several corporate employees cope with stress and depression, recalled her experience with her clients and said many mothers would be extremely worried about the health of their baby, and be worried about her family at the same time.

“Unfortunately, (there have been cases where) women came from places where they don’t have a supportive partner or family members. It could also be that a woman is trying to fullfil a lot of responsibilities — towards their baby, family and themselves In this case, the women will be stressed,” she said.

Explaining about difficulties women working in the corporate face after childbirth, Dr Sam said: “Yes, they do have two to three months of leaves, but they stress about going back to the work… , I will have the same position, I will have The same team, are the things being reassigned. How do I start from scratch.”

“Some of them who have gone back to work are finding the transition difficult. Even if colleagues are supportive, it could be a feeling of

“During COVID-19, I had some clients who were anxious about what will happen if they go to deliver, what if they get COVID, What if the baby gets COVID. I also have clients whose babies did get COVID right after birth,” she said.

How to tackle this stress

“Emotional support is important for a new mother. A mother needs to have that kind of support during and post-pregnancy. It is important to take care of the mother. One thing I observed is that… there is no work distribution at home. It is important to work distribution. It is important to have physical and mental rest. They should talk to their partners and prepare themselves when planning to go back to work.”

“Also, ensure you are having enough quality sleep. There would be challenges — you might see yourself more anxious, or sad, see certain thoughts creeping into you, certain self-harm thoughts, and degrading thoughts might also come. You might feel that Reaching out to your support system isn’t enough. Then that could be a cue to know that you need professional help. Mothers should also focus on self-care,” Dr Sam said.

Meanwhile, Dr Chhabra said, “For people living in metros, they would realise that they are living in a rat race. We need to take a break, find a ‘me time’ — that doesn’t mean watching video after video — but doing meditation, yoga, going for a walk, exercise — that are some ways to cope with this.”

There are effective treatments for depression and postpartum depression. Even severe depression can often be treated successfully. The key is to be aware of the situation and reach out for help as soon as possible.

(Edited by : Shoma Bhattacharjee)

First Published: IST


Ali Marpet Explains his Sudden Retirement from the Buccaneers


Tom Brady’s retirement announcement was both upsetting and surprising to almost anyone associated with the Tampa Bay Buccaneers organization. Despite being 44 years old, and having played in the NFL for 22 seasons, his MVP level performance, and disappointing playoff exit in his final season, left fans wanting more.

So if Tom Brady’s decision to retire at 44 years of age was a bit of a shock, then Ali Marpet’s decision to retire at 28 was a 9.0 on the richt(i)er(ment) scale.

Throughout his 7-year career, Ali Marpet exceeded all expectations on the field. He also managed to endear himself to fans, coaches, and teammates alike, off of it.


EXO Sehun Dating Rumor: ‘MONSTER’ Rapper Once Linked to Red Velvet Irene


EXO Sehun was swept up in a dating rumor several times, and one of those rumors involved his labelmate Red Velvet Irene. Never heard of it? Then, keep on reading!

EXO Sehun Dating Rumor With Red Velvet Irene – Here’s What Happened

As many fans know, EXO Sehun and Red Velvet Irene are artists under SM Entertainment. The two have been familiar with each other since their trainee days. But rumors about them being in a relationship only emerged in 2016 after they showed great chemistry during a pictorial for CéCi magazine.

But even before their photoshoot with the magazine, this gossip had been a hot topic among Korean netizens. In fact, the keyword “Irene Sehun” became a popular search term online.

ALSO READ: Red Velvet Seulgi Relationship 2022 – Truth Behind Dating Rumors With Model Julien Kang

During the pictorial with CéCi magazine, Sehun and Irene were paired as a romantic couple. Fans claimed that a spark between the two idols can be seen through the pictures and behind-the-scenes videos that the magazine shared. The chemistry they showed just appeared too real for it to be fake.

(Photo: Instagram: @oohsehun)
EXO Sehun Dating Rumor: ‘MONSTER’ Rapper Once Linked to Red Velvet Irene

Some netizens brought up the fact that EXO Kai and f(x) Krystal also showed amazing chemistry when they had a photoshoot with W magazine – and the two eventually became a real couple.

EXO Sehun Dating Rumor With Red Velvet Irene

(Photo : Twitter: @UncoverHallyu)
EXO Sehun Dating Rumor: ‘MONSTER’ Rapper Once Linked to Red Velvet Irene

After the dating rumor of EXO Sehun and Red Velvet Irene started circulating online, netizes dug up some past photos that serve as evidence of their relationship. The “pieces of proof” include a few pictures showing Sehun and Irene together in Hawaii (the images were captured after they allegedly went for a swim). That was the time when SM Entertainment took almost every one of their employees out to Hawaii for a vacation workshop.

Red Velvet Irene

(Photo: Instagram: @renebaebae)
EXO Sehun Dating Rumor: ‘MONSTER’ Rapper Once Linked to Red Velvet Irene

READ MORE: EXO Lay Relationship Status: Why Was the ‘Sheep’ Rapper Linked to Chinese Actress Yang Zi?

In addition to this, netizens pointed out that the two idols separately uploaded a photo to Instagram when they were allegedly in Hawaii. The pictures show the sky during sunset, making netizens speculate that the two were enjoying a romantic drive date and could be more than friends or senior-junior relationship.

EXO Sehun Dating Rumor With Red Velvet Irene

(Photo : Twitter: @UncoverHallyu)
EXO Sehun Dating Rumor: ‘MONSTER’ Rapper Once Linked to Red Velvet Irene

While EXO Sehun’s dating rumor with Red Velvet Irene was making rounds online, SM Entertainment didn’t release an official statement to address the topic.

What can you say about the rumor between the two SM artists? Tell us your opinion in the comments section below!

EXO Sehun Current Relationship and Ideal Type

EXO Sehun is presumably single right now considering his hectic schedule. Plus, the idol himself has not said anything about him dating someone (so far).

EXO Sehun

(Photo : Facebook: EXO)
EXO Sehun Dating Rumor With Red Velvet Irene

Concerning his ideal type, he previously shared that he likes a girl who would sincerely get worried about him. He is also into girls who would care for him if he’s hurt. The girl must also be a kind and bubbly person.

YOU MIGHT ALSO LIKE: EXO Sehun Workout Routine 2021: Here’s How You Can Get the Idol’s Sexy Body

When it comes to physical appearance, Sehun’s ideal type is someone who is neat, has round eyes, pale skin, and a natural good scent. Her ideal height would be between 167-169cm and her weight should be around 43 kg.

EXO Sehun

(Photo : Facebook: EXO)
EXO Sehun Dating Rumor With Red Velvet Irene

Other than that, EXO Sehun revealed that his latest ideal type is someone who puts on slippers. He emphasized that he cares about clothing. “I care about putting on slippers, looking sloppy – so you need to pay careful attention to clothing such as t-shirts, pants, and other things,” he said.

Do you have the characteristics and physical features EXO Sehun is looking for a girl?

For more K-Pop news and updates, keep your tabs open here at KpopStarz.

KpopStarz owns this article

Written by Maria Scott